May 30th, 2020 - Data from 2 phase 2 trials involving fam-trastuzumab deruxtecan-nxki (Enhertu) revealed the agent’s ability to induce responses in patients with HER2-positive metastatic colorectal cancer (CRC) and advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. Both studies had results presented at the 2020 ASCO Virtual Scientific Program.
May 30th, 2020 - Men with nonmetastatic castration-resistant prostate cancer (nmCRPC) lived significantly longer if they received an androgen signaling inhibitor (ASI) in addition to conventional androgen deprivation therapy (ADT), three large randomized trials of different drugs showed.
May 30th, 2020 - A pooled analysis of clinical trial data revealed that systemic therapy with cabozantinib (Cabometyx) in advanced renal cell carcinoma (RCC) induced reliable responses for patients regardless of whether or not they had received prior immunotherapy. Patients from both the phase 3 METEOR (NCT01865747) and the phase 2 Japanese C2001 (NCT03339219) trials comprised the efficacy population whose resu...
May 29th, 2020 - Although 84% of children with cancer survive 5 years or more, children with refractory, relapsed, and progressive high-risk malignancies have a poor median survival of 9.5 months. The German INFORM registry is a large prospective, noninterventional, multicenter study collecting clinical and molecular data on pediatric patients with refractory, relapsed, and progressive malignant cancers. The st...
May 29th, 2020 - Final survival results from three randomized, placebo-controlled trials, along with a safety analysis across all three, are helping to clarify the treatment landscape for nonmetastatic castration-resistant prostate cancer (nmCRPC). The results will be presented during the ASCO20 Virtual Scientific Program.
May 29th, 2020 - Participants in phase I oncology trials represent a patient population new to palliative care. These patients typically have remarkable symptoms, with a symptom burden comparable to other patients with cancer.1 Thomas J. Smith, MD, FASCO, of Johns Hopkins University, presented the results of a randomized trial evaluating a palliative care intervention (PCI) compared with usual care (UC) for pat...
May 19th, 2020 - In this meta-analysis that included 12 trials with 92 135 participants for the primary outcome measure, blood pressure lowering with antihypertensive agents, compared with control, was associated with the development of a composite dementia or cognitive impairment outcome in 7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years, a difference that was statistically significant.
Journal of Parkinson's Disease;
Jul 30th, 2019 - Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (amantadine) extended release capsules on these episodes.
Health care providers seeking information about appropriate coronavirus disease 2019 (COVID-19) treatment may now consult treatment guidelines developed by a panel of U.S. physicians, statisticians, and other experts. These guidelines are based on published and preliminary data and the clinical expertise of the panelists, many of whom are frontline clinicians caring for patients during the rapi...
The pharmaceutical company AstraZeneca halted large, late-stage global trials of its coronavirus vaccine on Tuesday because of a serious suspected adverse reaction in a participant, the company said. It is not yet known whether the reaction was directly caused by the company’s vaccine or was coincidental.
Spices such as cinnamon (Cinnamomum Spp.) have been of interest due to their phytochemical composition that exert hypoglycemic effects with potential for management of type 2 diabetes mellitus (T2DM). We summarize data from 27 manuscripts that include, one book chapter, 3 review articles, 10 randomized controlled trials, 4 systematic reviews with meta-analysis, and 9 preclinical studies. The...
The present systematic review and meta-analysis was conducted to investigate the effect of cinnamon supplementation on blood pressure and anthropometric indices in patients with type 2 diabetes.
Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression. Here, we performed a retrospective study on 13,981 patients with COVID-19 in Hubei Province, China, among which 1,219 received statins. Based on a mixed-effect Co...
Garlic supplements have shown effectiveness in reducing blood pressure in hypertensive patients, similarly to first‑line standard anti‑hypertensive medications. Kyolic garlic has also shown promise in improving cardiovascular health by reducing arterial stiffness, elevated cholesterol levels and blood ‘stickiness’. In addition, the prebiotic properties in garlic increase gut microbial richness ...
A long-standing resource for busy cardiovascular professionals in need of key takeaways on top clinical trials released during Cardiology’s most relevant meetings, ACC Cardiology Hour is an expert roundtable hosted by JACC Editor-in-Chief Valentin Fuster, MD, PhD, MACC. In this installment, Dr. Fuster is joined by David H. Adams, MD, FACC; Roxana Mehran, MD, FACC; Vivek Y. Reddy, MD; and Anu La...
The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). CDRC, in partnership with the FDA-NCATS CURE ID* platform, is a dedicated initiative designed to ca...
European Archives of Psychiatry and Clinical Neuroscience;
Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. PD is also characterized by non-motor symptoms such as sleep disturbances, cognitive deficits, and psychiatric disorders such as psychosis, depression, and anxiety. The pharmacological treatment for these symptoms is limited in ...
After receiving the green light from the FDA to move forward, Gilead is about to start trials of an inhaled version of remdesivir. We will screen healthy volunteers for Phase 1 trials this week and hope to begin studies in patients with COVID-19 in August. If the trials are successful, this could represent important progress. Remdesivir, our investigational antiviral medicine, is currently give...
The US government is pouring billions into Covid-19 vaccines, and candidates from three companies are moving along quickly: Moderna, Pfizer and Novavax. Here's what you need to know about them. These are among the dozens of Covid-19 vaccines in trials around the world as researchers rush to find a way to stop the pandemic. To help speed the process, the US government's Operation Warp Speed...
On August 23, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA)* for COVID-19 convalescent plasma for the treatment of hospitalized patients with COVID-19.1,2 The COVID-19 Treatment Guidelines Panel (the Panel) reviewed the available evidence from published and unpublished data on convalescent plasma for the treatment for COVID-19, including the FDA analys...